Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dendritic cell-Medical University of South Carolina-pancreatic adenocarcinoma
- Development stage
- Unknown
- Lead developer
- Medical University of South Carolina
- Modality
- Vaccines & Immunotherapeutics, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Administration
- Intradermal, Intratumoral
01
Overview
This is an investigational autologous dendritic cell-based immunotherapy vaccine developed by the Medical University of South Carolina (MUSC) for the treatment of locally advanced unresectable pancreatic adenocarcinoma. The therapy involves generating autologous dendritic cells (DCs) from a patient's peripheral blood and pulsing them with three specific HLA-A2-restricted tumor-associated peptide antigens: human telomerase reverse transcriptase (hTERT, TERT572Y), carcinoembryonic antigen (CEA; Cap1-6D), and survivin (SRV.A2). The vaccine is administered via intradermal or intratumoral injection in combination with Poly-ICLC (Hiltonol), a toll-like receptor 3 (TLR3) agonist that serves as an immune adjuvant. The goal of the therapy is to induce tumor-specific T cell responses against pancreatic cancer cells expressing these antigens.
- Brand names
- Hiltonol
- Other names
- Poly-ICLC and Dendritic CellshTERT/CEA/survivin-pulsed dendritic cell vaccineMUSC pancreatic cancer vaccine
Beyond the preview
Go deeper on dendritic cell-Medical University of South Carolina-pancreatic adenocarcinoma.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dendritic cell-Medical University of South Carolina-pancreatic adenocarcinoma.